Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS)

Saturday

2:55 PM

ThesisRecent positive clinical trial results and strategic partnerships are enhancing investor sentiment towards Sinopep-Allsino, signaling potential for revenue growth.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$1.9B	$2.3B	$2.7B
Rev. Growth	+19.6%	+20.9%	+13.5%
EPS	$1.06	$2.21	$2.79
EPS Growth	-20.9%	+108%	+26.5%
P/E (fwd)	26.4×	12.7×	10.0×

★ Analysts see FY2026 revenue reaching $2.3B — +20.9% growth in a single year.

Why Revenue Could Accelerate

01Recent clinical trial results for its lead oncology drug showed a 30% improvement in patient outcomes compared to existing therapies.
02The company secured a $200 million partnership with a leading global pharmaceutical firm for co-development of a new autoimmune treatment.
03The company is expanding its manufacturing capabilities in Southeast Asia, which could reduce production costs by 15%.
04Increased demand for innovative cancer therapies
05Expansion of biopharmaceuticals in emerging markets
06Regulatory approvals for new drug candidates, particularly in oncology
07Partnership announcements with larger pharmaceutical companies
08Clinical trial results that exceed market expectations

FY2025 Snapshot

Revenue: $1.9B
Rev. Growth: +19.6%
Gross Margin: 62.6%
Op. Margin: 20.6%
Net Margin: 17.1%
Net Income: $332M
NI Growth: -17.8%
EPS: $1.06
1Y Return: -33.5%

My Notes

"Our commitment to innovation and strategic partnerships positions us well for future growth."
Moat: The company's proprietary drug discovery platform and established relationships with regulatory bodies provide a strong competitive…
growth - The company is positioned for high growth due to its innovative product pipeline and expanding market presence.
Higher interest rates can increase the cost of capital for R&D financing, potentially slowing down new drug development and impacting…
Watch on earnings: Clinical trial success rates, Revenue from oncology therapeutics, Gross margin trends.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $2.3B to $2.7B as recent clinical trial results for its lead oncology drug showed a 30% improvement in patient outcomes compared.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.